Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJul 28, 2024
DataAggregated Company Financials
Companies7
  • 7D2.8%
  • 3M18.2%
  • 1Y7.1%
  • YTD12.0%

Over the last 7 days, the Pharma industry has risen 2.8%, driven by gains in Novartis and Roche Holding of 3.5% and 2.8%, respectively. Meanwhile, Galderma Group actually underperformed within the industry, shrinking 6.6% in the last week. In the last 12 months, the industry was up 7.1%. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 28 Jul 2024CHF 463.8bCHF 116.7bCHF 19.7b22.1x23.6x4x
Tue, 25 Jun 2024CHF 438.6bCHF 116.1bCHF 19.7b34.4x22.2x3.8x
Thu, 23 May 2024CHF 413.5bCHF 113.7bCHF 20.0b41.4x20.7x3.6x
Sat, 20 Apr 2024CHF 393.9bCHF 112.6bCHF 19.5b35.4x20.2x3.5x
Mon, 18 Mar 2024CHF 389.3bCHF 110.9bCHF 19.2b37.3x20.2x3.5x
Wed, 14 Feb 2024CHF 379.8bCHF 110.8bCHF 19.7b23.7x19.2x3.4x
Fri, 12 Jan 2024CHF 413.9bCHF 119.4bCHF 18.7b27x22.2x3.5x
Sun, 10 Dec 2023CHF 401.6bCHF 121.2bCHF 18.9b24.3x21.3x3.3x
Tue, 07 Nov 2023CHF 386.0bCHF 122.3bCHF 19.0b23.7x20.3x3.2x
Thu, 05 Oct 2023CHF 404.5bCHF 113.7bCHF 18.2b42.7x22.2x3.6x
Sat, 02 Sep 2023CHF 405.5bCHF 112.1bCHF 18.0b48.2x22.6x3.6x
Mon, 31 Jul 2023CHF 415.6bCHF 114.5bCHF 19.2b48x21.6x3.6x
Wed, 28 Jun 2023CHF 418.2bCHF 115.0bCHF 18.9b36.7x22.2x3.6x
Fri, 26 May 2023CHF 435.1bCHF 115.6bCHF 18.9b39x23x3.8x
Sun, 23 Apr 2023CHF 441.0bCHF 114.6bCHF 18.8b42.9x23.5x3.8x
Tue, 21 Mar 2023CHF 397.6bCHF 116.3bCHF 19.0b26.4x20.9x3.4x
Thu, 16 Feb 2023CHF 407.4bCHF 116.1bCHF 19.0b29.2x21.4x3.5x
Sat, 14 Jan 2023CHF 433.3bCHF 117.3bCHF 34.7b22.4x12.5x3.7x
Mon, 12 Dec 2022CHF 447.0bCHF 117.5bCHF 34.8b23.4x12.8x3.8x
Wed, 09 Nov 2022CHF 453.6bCHF 120.5bCHF 36.1b22.5x12.6x3.8x
Fri, 07 Oct 2022CHF 445.3bCHF 120.9bCHF 37.2b20.7x12x3.7x
Sun, 04 Sep 2022CHF 447.5bCHF 120.5bCHF 37.0b21.2x12.1x3.7x
Tue, 02 Aug 2022CHF 450.6bCHF 118.9bCHF 36.3b21x12.4x3.8x
Thu, 30 Jun 2022CHF 449.4bCHF 118.3bCHF 37.2b27.1x12.1x3.8x
Sat, 28 May 2022CHF 470.0bCHF 118.4bCHF 37.2b29.5x12.6x4x
Mon, 25 Apr 2022CHF 502.6bCHF 118.4bCHF 37.1b31.6x13.5x4.2x
Wed, 23 Mar 2022CHF 487.8bCHF 117.0bCHF 36.4b21.1x13.4x4.2x
Fri, 18 Feb 2022CHF 469.9bCHF 116.3bCHF 36.2b19.8x13x4x
Sun, 16 Jan 2022CHF 491.8bCHF 111.7bCHF 23.1b20.9x21.3x4.4x
Tue, 14 Dec 2021CHF 482.6bCHF 112.2bCHF 23.2b21.4x20.8x4.3x
Thu, 11 Nov 2021CHF 502.6bCHF 111.9bCHF 23.2b22.6x21.7x4.5x
Sat, 09 Oct 2021CHF 494.2bCHF 111.7bCHF 22.5b22x21.9x4.4x
Mon, 06 Sep 2021CHF 518.0bCHF 111.6bCHF 22.5b22.9x23x4.6x
Wed, 04 Aug 2021CHF 521.8bCHF 111.6bCHF 22.5b24.4x23.2x4.7x
Price to Earnings Ratio

23.2x


Total Market Cap: CHF 521.8bTotal Earnings: CHF 22.5bTotal Revenue: CHF 111.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 18.6x202220232024
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 23.6x which is higher than its 3-year average PE of 18.6x.
  • The industry is trading close to its 3-year average PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 4.4% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.57%
Healthcare3.28%
Pharma2.76%
Pharma2.76%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVN NovartisCHF 97.453.5%
+CHF 6.6b		8.0%PE22.1x
ROG Roche HoldingCHF 286.002.8%
+CHF 6.0b		6.2%PE21.5x
SDZ Sandoz GroupCHF 35.914.5%
+CHF 657.5m		n/aPE226.9x
DESN Dottikon ES HoldingCHF 254.502.2%
+CHF 76.0m		8.5%PE43.6x
COPN Cosmo PharmaceuticalsCHF 70.603.2%
+CHF 35.3m		60.8%PE17x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

COPN

CHF 70.60

Cosmo Pharmaceuticals

7D

3.2%

1Y

60.8%

ROG

CHF 286.00

Roche Holding

7D

2.8%

1Y

6.2%

GALD

CHF 66.12

Galderma Group

7D

-6.6%

1Y

n/a

SDZ

CHF 35.91

Sandoz Group

7D

4.5%

1Y

n/a

NOVN

CHF 97.45

Novartis

7D

3.5%

1Y

8.0%

DESN

CHF 254.50

Dottikon ES Holding

7D

2.2%

1Y

8.5%

Dottikon ES Holding AG (VTX:DESN) Not Flying Under The Radar

Jul 17
Dottikon ES Holding AG (VTX:DESN) Not Flying Under The Radar

CURN

CHF 6.60

Curatis Holding

7D

19.6%

1Y

n/a

NWRN

CHF 8.02

Newron Pharmaceuticals

7D

1.5%

1Y

53.1%

KNRS

CHF 16.13

Kinarus Therapeutics Holding

7D

5.9%

1Y

-66.7%